Changes in Type 2 Diabetes Medications Among Primary Care Patients After California’s 2022 Medicaid Expansion
Main finding · Prescription of newer T2D medication classesResult — go to the resultMonthly rate of increase in odds 6%Authors' conclusion
Medi-Cal expansion was effective in changing prescription patterns for older undocumented immigrants with T2D. Although the older undocumented immigrants were prescribed newer drugs at a much lower level than were documented immigrants, they ended at a similar level as the documented patients by the end of the study period.
Study context
- Population
- Primary care patients with T2D at two Federally Qualified Health Centers (FQHCs) in Los Angeles County, January 2019 to June 2023, around California's May 2022 Medicaid expansion to low-income undocumented immigrants aged ≥50 years
- Participants
- 4,601 patients20,420 encounters
- Exposure
- Older undocumented vs younger undocumented vs documented patients
- Outcome
- Prescription of newer T2D medications (e.g. GLP-1 RA, SGLT2i) and changes over time
Methodological detailstwo Federally Qualified Health Centers, generalized linear mixed models with patient-level random intercepts
- Two Federally Qualified Health Centers
- Generalized linear mixed models with patient-level random intercepts
Main finding
Prescription of newer T2D medication classes
Monthly rate of increase in odds
6%
As reported in the abstract
Observational data: associations, not effects.
Original publication
Changes in Type 2 Diabetes Medications Among Primary Care Patients After California’s 2022 Medicaid Expansion. Diabetes Care. Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →